Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity.

Abstract

BACKGROUND:

Circulating autoantibodies against FcepsilonRI, IgE, or both occur in approximately one third of patients with chronic idiopathic urticaria (CIU), but not all autoantibodies initiate histamine release.

OBJECTIVE:

We sought to classify patients with CIU into subsets on the basis of serum bioactivity and immunoreactivity and to examine the relationship between newly defined subtype and disease severity.

METHODS:

Sera from patients with CIU (n = 78), dermog-raphism (n = 15), and cholinergic urticaria (n = 10) and sera from healthy subjects (n = 39) were analyzed by means of Western blot analysis for anti-FcepsilonRI autoantibodies and for histamine release from basophils and dermal mast cells. In vivo reactivity of autologous serum was tested by means of intradermal injection, and CIU severity was determined on the basis of clinical interview.

RESULTS:

We classified sera from patients with CIU into 5 subsets: immunoreactive histamine-releasing anti-FcepsilonRI autoantibodies (n = 20 [26%]); immunoreactive anti-FcepsilonRI autoantibodies without histamine-releasing activity (n = 12 [15%]); anti-IgE-like autoantibodies (n = 7 [9%]); serum containing a mast cell-specific histamine-releasing factor (n = 7 [9%]); and sera with no identifiable factor (n = 32 [41%]). Patients with serum histamine-releasing activity had more severe urticaria than patients without such activity. Positive skin test responses to autologous sera were associated with histamine-releasing anti-FcepsilonRI autoantibodies but not with non-histamine-releasing anti-FcepsilonRI autoantibodies. Neither healthy subjects nor patients with dermographism or cholinergic urticaria had his-tamine-releasing anti-FcepsilonRI autoantibodies.

CONCLUSION:

These data support the specificity of functional anti-FcepsilonRI autoantibodies to CIU. The identification of distinctive subsets of patients suggests that other pathogenic mechanisms occur in CIU in addition to direct ligation of FcepsilonRI by autoantibodies causing dermal mast cell degranulation. Elucidating these mechanisms might lead to new treatments for CIU.

• Authors: Ruth A Sabroe, Edda Fiebiger, David M Francis, Dieter Maurer, Paul T Seed, Clive E h Grattan, Anne Kobza Black, Georg Stingl, Malcolm W Greaves, Robert M Barr
• Journal: The Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 110 Issue 3 Pg. 492-9 (Sep 2002) ISSN: 0091-6749 [Print] United States
• PMID: 12209101 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Anti-Idiotypic
• Autoantibodies
• Receptors, IgE
• anti-IgE antibodies

Topics

• Adolescent
• Adult
• Antibodies, Anti-Idiotypic (immunology)
• Autoantibodies (blood, immunology)
• Blotting, Western
• Chronic Disease
• Histamine Release
• Humans
• Middle Aged
• Receptors, IgE (immunology)
• Skin Tests
• Urticaria (classification, diagnosis, immunology)